GGrantIndex
← Leaderboards

Thomas Rudge

Battelle Centers/Pub Hlth Res & Evaluatn

Google Scholar ↗PubMed ↗ORCID ↗
$58,444,221
Attributed
$58,444,221
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $26.3M · FY2018–25
$50M$37.5M$25M$12.5M$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$58,444,221 · 3

By mechanism

N01$58,444,221 · 3

Top collaborators

No co-investigators on record.

Most similar at Battelle Centers/Pub Hlth Res & Evaluatn

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Services”

Research focus

ServicesProduct DevelopmentCommunicable DiseasesContractsFeasibility StudiesVaccinesEvaluation/TestingTesting ServicesNovel VaccinesBiologicalInvestigational New Drug ApplicationLicensingVaccine CandidateBioterrorismEmerging Communicable DiseasesSamplingImmunogenicityEfficacy TestingVaccine DevelopmentSafetyOffice Of Administrative ManagementToxicologyAreaReporting

Grant awards (56)

Task V15: Development of Assays and Reagents for mpox Vaccines$793,164
N01 · FY2025 · AI · contact PI
Task V11: General Safety Toxicity Testing$629,831
N01 · FY2025 · AI · contact PI
Task V15: Development of Assays and Reagents for mpox Vaccines$484,919
N01 · FY2025 · AI · contact PI
Task V11: General Safety Toxicity Testing for Influenza$334,969
N01 · FY2025 · AI · contact PI
EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES$10,000
N01 · FY2025 · AI · contact PI
Task V11: General Safety Toxicity Testing, SARS-CoV-2$6,134,108
N01 · FY2024 · AI · contact PI
Task V20: Hamster Sarbecovirus Challenge Model for SARS-CoV-2 Vaccine Testing$2,365,162
N01 · FY2024 · AI · contact PI
Task V11: General Safety Toxicity Testing$1,154,109
N01 · FY2024 · AI · contact PI
Task V15: Development of Assays and Reagents for mpox Vaccines$632,480
N01 · FY2024 · AI · contact PI
Task V11: General Safety Toxicity Testing$605,930
N01 · FY2024 · AI · contact PI
Task V15: Development of Assays and Reagents for mpox Vaccines$393,164
N01 · FY2024 · AI · contact PI
Task X14: Evaluation of Filovirus Vaccines in a General Use Prophylaxis (GUP) Immunogenicity and Ebolavirus Challenge Studies to Identify Potential Correlates of Protection$310,523
N01 · FY2024 · AI · contact PI
Task V01: Administrative Support for Evaluation and Testing Services (ETS) for Vaccines and other Biologics for Infectious Diseases$163,946
N01 · FY2024 · AI · contact PI
Task V11: General Safety Toxicity Testing$2,035,442
N01 · FY2023 · AI · contact PI
Task V18: STUDY TO EVALUATE THE EFFICACY OF TOXIN IN ANIMAL MODEL$1,139,090
N01 · FY2023 · AI · contact PI
Task V17: CREATION OF INTERNATIONAL VIRUS STANDARDS$657,850
N01 · FY2023 · AI · contact PI
TASK V15: DEVELOPMENT OF ASSAYS AND REAGENTS FOR VACCINES$484,304
N01 · FY2023 · AI · contact PI
Task X7: Preparedness for Testing Influenza Vaccines$337,334
N01 · FY2023 · AI · contact PI
Task V01: Administrative Support for Evaluation and Testing Services (ETS) for Vaccines and other Biologics for Infectious Diseases$159,650
N01 · FY2023 · AI · contact PI
TASK V13: DEEP ANTIBODY PROFILING FOR INFECTION AND VACCINATION$56,576
N01 · FY2023 · AI · contact PI
Task V02: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates$2,467,841
N01 · FY2022 · AI · contact PI
TASK V17: DEVELOPMENT OF ASSAYS AND REAGENTS FOR MONKEYPOX VACCINES$1,045,131
N01 · FY2022 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$903,613
N01 · FY2022 · AI · contact PI
TASK V13: DEEP ANTIBODY PROFILING FOR RSV INFECTION AND VACCINATION$787,348
N01 · FY2022 · AI · contact PI
TASK V14: CREATION OF A MARBURGVIRUS INTERNATIONAL STANDARD$656,189
N01 · FY2022 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$269,886
N01 · FY2022 · AI · contact PI
Task V12: CLINICAL SAMPLE TESTING FOR ZIKA VIRUS VACCINES$211,025
N01 · FY2022 · AI · contact PI
Task V01: Administrative Support for Evaluation and Testing Services (ETS) for Vaccines and other Biologics for Infectious Diseases$155,354
N01 · FY2022 · AI · contact PI
Task V11: General Safety Toxicity Testing$151,942
N01 · FY2022 · AI · contact PI
Task V02: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates$134,146
N01 · FY2022 · AI · contact PI
Task V06: Immunogenicity and efficacy testing of COVID-19 vaccine candidates in nonhuman primates$1,064,710
N01 · FY2021 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$777,134
N01 · FY2021 · AI · contact PI
Task V03: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates$488,832
N01 · FY2021 · AI · contact PI
Task V10: Clinical Sample Evaluation for Anthrax Vaccines$338,804
N01 · FY2021 · AI · contact PI
Task V11: General Safety Toxicity Testing$252,972
N01 · FY2021 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$252,372
N01 · FY2021 · AI · contact PI
Task V7: Clinical and NHP Sample Testing for SARS-CoV-2 Biological Product Candidates$172,276
N01 · FY2021 · AI · contact PI
Task V01: Administrative Support for Evaluation and Testing Services (ETS) for Vaccines and other Biologics for Infectious Diseases$150,952
N01 · FY2021 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$139,564
N01 · FY2021 · AI · contact PI
Task V7: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine Candidates$106,598
N01 · FY2021 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$7,094,023
N01 · FY2020 · AI · contact PI
Task V12: Clinical Sample Testing for SARS-CoV-2 Vaccine Candidates$6,398,512
N01 · FY2020 · AI · contact PI
Task V03: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates$4,017,825
N01 · FY2020 · AI · contact PI
Task V05: Development of Assays and Reagents for Coronavirus Vaccines$2,950,261
N01 · FY2020 · AI · contact PI
Task V07: Immunogenicity and efficacy testing of COVID-19 vaccine candidates in nonhuman primates$2,429,847
N01 · FY2020 · AI · contact PI
Task V2: Clinical Sample Testing from Influenza Clinical Trials for HAI, MN and NA Activity$1,477,780
N01 · FY2020 · AI · contact PI
Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates$892,055
N01 · FY2020 · AI · contact PI
Task V07: Qualification of a Shigella Serum Bactericidal Assay$692,451
N01 · FY2020 · AI · contact PI
Task V01: Administrative Support for Evaluation and Testing Services (ETS) for Vaccines and other Biologics for Infectious Diseases$145,907
N01 · FY2020 · AI · contact PI
Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates$113,397
N01 · FY2020 · AI · contact PI
Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates$98,800
N01 · FY2020 · AI · contact PI
Task V04: Clinical Sample Testing Using Intracellular Flow Cytometry using samples from a Phase 1 clinical trial evaluating an influenza vaccine candidate$838,705
N01 · FY2019 · AI · contact PI
Task V03: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates$616,957
N01 · FY2019 · AI · contact PI
Task V01: Administrative Support for Evaluation and Testing Services (ETS) for Vaccines and other Biologics for Infectious Diseases$140,702
N01 · FY2019 · AI · contact PI
Task X27:Evaluation of a novel adjuvant for the recombinant Plague Vaccine$994,946
N01 · FY2018 · AI · contact PI
Task Z01:$132,813
N01 · FY2018 · AI · contact PI